Java at m4 Munich Biomarker Conference

Java’s CSO, James McRedmond, will be attending the 4th Munich Biomarker Conference┬áNovember 25th-26th, 2014. James will be discussing with other attendees how our custom assay development services can be used to discover and characterise biomarkers in clinical trials. We will also be discussing our R&D project, identifying biomarkers in cardiovascular disease that provide early clinical proof of concept and accelerate drug development.

Looking forward to the Development Strategies session, and hopefully some productive meetings during the conference.